Table 4

Multivariable analyses of factors associated with hospital length of stay or costs among patients who survived at least 30 days
Variable Length of stay (LOS) (GLM gamma-identity link, N = 163) Total cost (GLM gamma-log link, N = 162)
β estimate (days) 95% Wald CI for β estimate Exp (β) estimate 95% Wald CI for Exp (β) estimate
Antifungal Therapy
Other vs. voriconazole 5.33 (−3.43, 14.10) 1.527 (.996, 2.342)
Echinocandins vs. voriconazole −1.76 (−7.76, 4.23) .925 (.729, 1.174)
Mechanical Ventilation 7.32 (−.218, 14.87) 1.854**** (1.41, 2.44)
Acute Renal Failure 8.57 (−1.08, 18.23) 1.437** (1.10, 1.87)
Area
 South vs. West −3.08 (−14.18, 8.03) .591* (.382, .917)
 Northeast vs. West −4.88 (−16.98, 7.23) .558* (.358, .872)
 Midwest vs. West −4.27 (−15.81, 7.28) .588* (.378, .913)
APR-severity 5.71 (−0.68, 12.09) 1.570* (1.01, 2.24)
Teaching Hospital −1.25 (−5.93, 3.43) 1.015 (.829, 1.242)
Payer
 Others vs. Medicare -.712 (−8.14, 6.71) .964 (.680, 1.37)
 Commercial-Indemnity vs. Medicare -.814 (−7.84, 6.21) .860 (.657, 1.12)
 Managed Care vs. Medicare 4.34 (−3.04, 11.71) 1.603** (1.16, 2.22)
 Medicaid vs. Medicare 5.69 (−8.06, 19.44) 1.385 (.963, 1.99)
Timing of antifungal therapy1 1.28**** (0.89, 1.67) 1.035**** (1.02, 1.05)

*p < 0.05 ** p < 0.01 ***p < 0.001 **** p < 0.0001.

1 AF index event (defined as days from hospital admission to initial antifungal start date).

Baddley et al.

Baddley et al. BMC Infectious Diseases 2013 13:29   doi:10.1186/1471-2334-13-29

Open Data